Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XABNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1.1.4NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CH.1.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FT.4NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FT.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XALNSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XALNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBWNSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBWNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.3.7NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.3.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAY.1.1.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XAY.1.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.19NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.61 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.61 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.75.6NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.75.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GC.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
GC.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.16NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BQ.1.1.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.524NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.524NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.38NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.5.2.38NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.15.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.1.15.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.15NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.59 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.59 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBRNSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBRNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DJ.1.1.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
DJ.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.10.4NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.10.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
FF.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FF.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DN.1.1.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
DN.1.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.626NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.626NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.629NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.629NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GA.9NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
GA.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EP.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used